Top

Published in:

Open Access 01-12-2016 | Commentary

Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go

Author: Rana Rizk

Published in: BMC Nephrology | Issue 1/2016

Abstract

Hyperphosphatemia management is integral to the management of patients with chronic kidney disease. This mineral abnormality is associated with greater costs, but so is its management, especially with the use novel phosphate binders. The economic evaluation of these pharmaceutical agents is increasingly needed to provide evidence for value of money spent and inform resource allocation. Recently, Nguyen et al. explored the economical attractiveness of Sevelamer relative to Calcium Carbonate among patients with chronic kidney disease not yet on dialysis and concluded that the former was cost-effective. The current commentary discusses the results of this analysis and sheds light on the methodological challenges of economic evaluations in this field.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–17.CrossRefPubMed

Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34–8.CrossRefPubMed

Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519–30.CrossRefPubMed

White DA, Odedina F, Xiao H, Campbell E, Segal R. The economic burden of end-stage renal disease with hyperphosphatemia. Dis Manag Health Outcomes. 2012;14:99–106.CrossRef

Kestenbaum B. Serum Phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–8.CrossRefPubMed

Selamet U, Tighiouart H, Sarnak MJ, et al. Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3–5: The Modification of Diet in Renal Disease Study. Kidney Int. 2016;89:176–84.CrossRefPubMedPubMedCentral

Mehrotra R, Peralta CA, Chen S-C, et al. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int. 2013;84:989–97.CrossRefPubMedPubMedCentral

White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007;71:312–7.CrossRefPubMed

Brousselle A, Lessard C. Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path. Soc Sci Med. 2011;72:832–9.CrossRefPubMed

10.

Rizk R, Hiligsmann M, Karavetian M, Evers SM. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review. Nephrology. 2016;21:178–87.CrossRefPubMed

11.

Vegter S, Tolley K, Keith MS, Postma MJ. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health. 2011;14:852–8.CrossRefPubMed

12.

Thompson M, Bartko-Winters S, Bernard L, Fenton A, Hutchison C, Di Iorio B. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ. 2013;16:744–55.CrossRefPubMed

13.

Nguyen HV, Bose S, Finkelstein E. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. BMC Nephrol. 2016;17:45.CrossRefPubMedPubMedCentral

14.

Di Iorio B, Bellasi A, Russo D, on behalf of the INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: A randomized study. Clin J Am Soc Nephrol. 2012;7:487–93.CrossRefPubMed

15.

Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409–18.CrossRefPubMed

16.

Goeree R, Burke N, O’Reilly D, Manca A, Blackhouse G, Tarride JE. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr Med Res Opin. 2007;23:671–82.CrossRefPubMed

17.

Elliott RA, Putman K, Davies J, Annemans L. A review of the methodological challenges in assessing the cost effectiveness of pharmacist interventions. PharmacoEconomics. 2014;32:1185–99.CrossRefPubMed

18.

Grima DT, Bernard MLM, Dunn ES, McFarlane PA, Mendelssohn DC. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis. PharmacoEconomics. 2012;30:981–9.CrossRefPubMed

19.

John-Baptiste A, Bell C. Industry sponsored bias in cost effectiveness analyses. BMJ. 2010;341:c5350.CrossRefPubMed

20.

Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ. 2003;326:1167–70.CrossRefPubMedPubMedCentral

21.

Evers SMAA, Hiligsmann M, Adarkwah CC. Risk of bias in trial-based economic evaluations: Identification of sources and bias-reducing strategies. Psychol Health. 2015;30:52–71.CrossRefPubMed

22.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. 2009;76 Suppl 113:1–130.

23.

Dasgupta I, Shroff R, Bennett-Jones D, McVeigh G. Management of hyperphosphataemia in chronic kidney disease: Summary of National Institute for Health and Clinical Excellence (NICE) guideline. Nephron Clin Pract. 2013;124:1–9.CrossRefPubMed

Title: Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go
Author: Rana Rizk
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-016-0286-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

The possible involvement of intestine-derived IgA1: a case of IgA nephropathy associated with Crohn’s disease

Knowledge, barriers and facilitators of exercise in dialysis patients: a qualitative study of patients, staff and nephrologists

Prevalence of intradialytic hypotension, clinical symptoms and nursing interventions - a three-months, prospective study of 3818 haemodialysis sessions

Cells of renin lineage express hypoxia inducible factor 2α following experimental ureteral obstruction

RhoA deficiency disrupts podocyte cytoskeleton and induces podocyte apoptosis by inhibiting YAP/dendrin signal

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page